Highlights by Rana McKay from ASCO GU25 Day 1
The 2025 ASCO Genitourinary Cancers Symposium is currently taking place from February 13-15 at Moscone West in San Francisco. This event is showcasing the latest research and best practices in genitourinary (GU) cancer care, with expert talks and engaging discussions. Attendees are experiencing a comprehensive program that includes keynote presentations, panel discussions, and interactive sessions focused on advancements in the diagnosis, treatment, and patient management of GU cancers.
The symposium provides healthcare professionals with an invaluable opportunity to engage with leading researchers, gain insights into emerging therapies, and enhance their clinical practices. It is co-sponsored by the American Society of Clinical Oncology, the American Society for Radiation Oncology, and the Society of Urologic Oncology.
Rana McKay, Associate Professor of Medicine at University of California San Diego, shared about this conference on X:
Actively accruing patients with mCRPC post ARPI
“Join us at GU25 L34 TIP highlighting the PREDICT trial. DNA/RNA biomarker based precision medicine trial through the Alliance for Clinical Trials in Oncology. Actively accruing patients with mCRPC post ARPI.”
First presentation at GU25 by George Zhao
“Amazing first presentation at GU25 by George Zhao on the application of PORTOS to predict dose response to radiation. Work originally conceived by Felix Feng giant in the field.”
Comprehensive review of radium 223
“Check out our poster featuring comprehensive review of radium 223 activity in the post ARPI era! GU25 Looking at predictors of completion of therapy.”
Evaluating treatment preference in the mHSPC setting
“Excellent work by our cooperative groups evaluating treatment preference in the mHSPC setting.”
Meeting amazing friends at GU25
“Meeting amazing friends at GU25! Love Alexandra Drakaki…mover and shaker in the bladder space. And fellow West Coaster.”
Hershey Dudipala presenting data on molecular profiling of intraductal prostate cancer
“Great to see our amazing fellow Hershey Dudipala presenting data on our molecular profiling of intraductal prostate cancer at GU25! Associated with NEPC signature, DLL3 expression and worse molecular features.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023